INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas

Andrea Tannapfel(Leipzig University), Christian Wittekind, Alexander Katalinic(German Cancer Research Center), Claudia Busse(Leipzig University), Lars Weinans(Leipzig University), Felix Geißler, Johann Hauss, Markus Benicke(Leipzig University)

Oncogene

October 25, 2001

10.1038/sj.onc.1204902

Cited by 132

Related Papers

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

|The Lancet Oncology|2016|738

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial

|The Lancet Oncology|2015|723

Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study

|The Lancet Oncology|2021|477

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

|Annals of Oncology|2016|344

Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer)

|British Journal of Dermatology|2003|342